אמיפמפרידין (Hebrew Wikipedia)

Analysis of information sources in references of the Wikipedia article "אמיפמפרידין" in Hebrew language version.

refsWebsite

Global rank Hebrew rank

14nih.gov

4^th place

18^th place

4bizjournals.com

407^th place

1,231^st place

4fda.gov

447^th place

285^th place

3europa.eu

68^th place

170^th place

2nytimes.com

7^th place

32^nd place

2fiercebiotech.com

low place

2nbcnews.com

137^th place

291^st place

1england.nhs.uk

low place

1sciencemag.org

857^th place

207^th place

1harvard.edu

18^th place

109^th place

1statnews.com

8,771^st place

3,078^th place

1yixiblog.wordpress.com

low place

1pemagazine.fr

low place

1pharmaceutical-technology.com

low place

1bbc.com

20^th place

65^th place

1bmj.com

1,226^th place

378^th place

1who.int

195^th place

160^th place

1raredr.com

low place

1sante.fr

8,603^rd place

low place

1drugs.com

399^th place

650^th place

bbc.com

Adrian Goldberg Drug firms accused of exploiting loophole for profit BBC News.

bizjournals.com

Ron Leuty BioMarin licenses North American rights to rare disease drug, invests $5M in Florida company BioMarin licenses North American rights to rare disease drug, invests $5M in Florida company
Brian Bandell Shares of Catalyst Pharmaceuticals soar 42% on FDA news South Florida Business Journal.
Celia Ampel Catalyst Pharma stock rises 5% after firm hits FDA milestone South Florida Business Journal.
Debora Lima Catalyst Pharmaceuticals files new drug application with FDA South Florida Business Journa.

bmj.com

Open letter to prime minister David Cameron and health secretary Andrew Lansley BMJ. 341: c6466. doi:10.1136/bmj.c6466. PMID 21081599.

drugs.com

J.Stewart BPharm Firdapse Approval History Drugs.com

england.nhs.uk

engage.england.nhs.uk

Evidence Review: Amifampridine phosphate for the treatment of LambertEaston Myasthenic Syndrome

europa.eu

ema.europa.eu

Firdapse Summary of Product Characteristics EMA. February 11, 2010
Public summary of opinion on orphan designation 3,4 diaminopyridine phosphate for the for the treatment of Lambert-Eaton myasthenic syndrome EMA.
ASSESSMENT REPORT FOR Zenas EMA CHMP committee. 2009

fda.gov

accessdata.fda.gov

Search Orphan Drug Designations and Approvals
Search Orphan Drug Designations and Approvals FDA
Search Orphan Drug Designations and Approvals www.accessdata.fda.gov. FDA
Search Orphan Drug Designations and Approvals U.S. Food and Drug Administration

fiercebiotech.com

Ben Adams Catalyst Pharmaceuticals hit by FDA extra studies request for Firdapse FierceBiotech
Ben Adams Catalyst to ax 30% of workforce in wake of FDA trial demands FierceBiotech

harvard.edu

blog.petrieflom.law.harvard.edu

Dalia Deak Jacobus and Catalyst Continue to Race for Approval of LEMS Drug Bill of Health.

nbcnews.com

nih.gov

ncbi.nlm.nih.gov

Argov Z (Oct 2009). "Management of myasthenic conditions: nonimmune issues". Current Opinion in Neurology. 22 (5): 493–7. doi:10.1097/WCO.0b013e32832f15fa. PMID 19593127
Angela Abicht, MD, Juliane Müller, S, PhD, and Hanns Lochmüller, MD. Congenital Myasthenic Syndromes GeneReviews. University of Washington, Seattle.
Keogh M, Sedehizadeh S, Maddison P (2011). "Treatment for Lambert-Eaton myasthenic syndrome". The Cochrane Database of Systematic Reviews (2): CD003279. doi:10.1002/14651858.CD003279.pub3. PMID 21328260.
Tyler B. Tarr, Peter Wipf, and Stephen D. Meriney Synaptic pathophysiology and treatment of Lambert-Eaton myasthenic syndromeMolecular Neurobiology. 52 (1): 456–63. doi:10.1007/s12035-014-8887-2. PMC 4362862. PMID 25195700.
G E Kirsch and T Narahashi 3,4-diaminopyridine. A potent new potassium channel blocker. Biophys J. 22 (3): 507–12. doi:10.1016/s0006-3495(78)85503-9. PMC 1473482. PMID 667299.
Drummond, M; Towse, A (May 2014). "Orphan drugs policies: a suitable case for treatment". The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care. 15 (4): 335–40. doi:10.1007/s10198-014-0560-1. PMID 24435513.
Open letter to prime minister David Cameron and health secretary Andrew Lansley BMJ. 341: c6466. doi:10.1136/bmj.c6466. PMID 21081599.
Hawkes N, Cohen D (2010). "What makes an orphan drug?". BMJ. 341: c6459. doi:10.1136/bmj.c6459. PMID 21081607.
Vedeler, CA; Antoine, JC; Giometto, B; Graus, F; Grisold, W; Hart, IK; Honnorat, J; Sillevis Smitt, PA; Verschuuren, JJ; Voltz, R; Paraneoplastic Neurological Syndrome Euronetwork. (July 2006). "Management of paraneoplastic neurological syndromes: report of an EFNS Task Force". European Journal of Neurology. 13 (7): 682–90. doi:10.1111/j.1468-1331.2006.01266.x. PMID 16834698.
Danial E. Baker Breakthrough Drug Approval Process and Postmarketing ADR Reporting Hospital Pharmacy. 48 (10): 796–8. doi:10.1310/hpj4810-796. PMC 3859287. PMID 24421428.
Burns, TM, et al.I (February 2016). "Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine". Muscle & Nerve. 53 (2): 165–8. doi:10.1002/mus.25009. PMID 26662952.
Solari, A.; Uitdehaag, B.; Giuliani, G.; Pucci, E.; Taus, C. (2002). "Aminopyridines for symptomatic treatment in multiple sclerosis". The Cochrane Database of Systematic Reviews (4): CD001330. doi:10.1002/14651858.CD001330. ISSN 1469-493X. PMID 12804404.
Sedehizadeh, S; Keogh, M; Maddison, P (2012). "The use of aminopyridines in neurological disorders". Clinical Neuropharmacology. 35 (4): 191–200. doi:10.1097/WNF.0b013e31825a68c5. PMID 22805230.